Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2022
ASCO 2022
ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?
Fierce Pharma
Sun, 06/5/22 - 11:40 pm
ASCO 2022
Pfizer
Ibrance
HR-positive
HER2-negative breast cancer
breast cancer
clinical trials
ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?
Fierce Pharma
Fri, 06/3/22 - 10:27 am
AbbVie
JNJ
ASCO 2022
FDA
Imbruvica
MCL
ASCO Preview: Immutep, InxMed and Faron Release New Clinical Findings
BioSpace
Tue, 05/31/22 - 10:49 am
ASCO 2022
IMMUTEP
non-small cell lung cancer
InxMed
ovarian cancer
Faron Pharmaceuticals
solid tumors
ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups
Fierce Pharma
Mon, 05/30/22 - 10:18 am
ASCO 2022
Merck
Keytruda
lung cancer
ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population
Fierce Pharma
Fri, 05/27/22 - 10:33 am
ASCO 2022
JNBJ
Legend Biotech
Carvykti
CAR-T
Multiple Myeloma
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug
Fierce Pharma
Fri, 05/27/22 - 10:31 am
ASCO 2022
Seagen
Takeda
Adcetris
lymphoma
Roche trumpets new glofitamab data in lymphoma at ASCO
Pharmaforum
Fri, 05/27/22 - 10:24 am
Roche
ASCO 2022
glofitamab
lymphoma
bispecific antibodies
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data
Fierce Pharma
Fri, 05/27/22 - 10:21 am
ASCO 2022
Novartis
Gleevec
Scemblix
CML
chronic myeloid leukemia
ASCO: Is another pan-tumor drug on the horizon? Johnson & Johnson thinks Balversa could be it
Fierce Pharma
Fri, 05/27/22 - 10:19 am
ASCO 2022
JNJ
Janssen
pan-tumor
Balversa
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
Fierce Biotech
Fri, 05/27/22 - 10:17 am
ASCO 2022
Merck
Keytuda
Lynparza
Lenvima
3 cancer drug studies to watch at next month’s ASCO meeting
BioPharma Dive
Thu, 05/26/22 - 10:47 pm
ASCO 2022
AstraZeneca
Enhertu
Gilead Sciences
Trodelvy
Roche
tiragolumab
cancer
Pages
« first
‹ previous
1
2